A citation-based method for searching scientific literature

Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu, Christophe Severin, Linda Rangell, Ralph Schwall, Lukas Amler, Dineli Wickramasinghe, Robert Yauch. Cancer Res 2006
Times Cited: 329







List of co-cited articles
991 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
408
54

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
368
49

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
320
48

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu,[...]. Clin Cancer Res 2016
206
39

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
34


Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger,[...]. J Thorac Oncol 2016
166
29

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria S Tretiakova, Vidya Nallasura, Edward A Fox, Mark Hansen, Erik Schaefer, Katsuhiko Naoki, Alan Lader,[...]. Cancer Res 2005
442
28

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
108
27

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Ryoichi Onozato, Takayuki Kosaka, Hiroyuki Kuwano, Yoshitaka Sekido, Yasushi Yatabe, Tetsuya Mitsudomi. J Thorac Oncol 2009
212
24

Targeting MET in cancer: rationale and progress.
Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier, George Vande Woude. Nat Rev Cancer 2012
23

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
197
23

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
P Peschard, T M Fournier, L Lamorte, M A Naujokas, H Band, W Y Langdon, M Park. Mol Cell 2001
309
22

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
170
22

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S Shames, Dustin Smith, Wei Yu, Virginia E Paton,[...]. J Clin Oncol 2017
158
22

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Federico Cappuzzo, Antonio Marchetti, Margaret Skokan, Elisa Rossi, Sujatha Gajapathy, Lara Felicioni, Maela Del Grammastro, Maria Grazia Sciarrotta, Fiamma Buttitta, Matteo Incarbone,[...]. J Clin Oncol 2009
432
21

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
136
21

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
20

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
131
20

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Giorgio Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto, Fabrice Barlesi, Wallace Akerley, Sergey Orlov, Armando Santoro, David Spigel,[...]. J Clin Oncol 2015
195
18

An overview of the c-MET signaling pathway.
Shawna Leslie Organ, Ming-Sound Tsao. Ther Adv Med Oncol 2011
409
18

Met, metastasis, motility and more.
Carmen Birchmeier, Walter Birchmeier, Ermanno Gherardi, George F Vande Woude. Nat Rev Mol Cell Biol 2003
17

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Rebecca S Heist, Lecia V Sequist, Darrell Borger, Justin F Gainor, Ronald S Arellano, Long P Le, Dora Dias-Santagata, Jeffrey W Clark, Jeffrey A Engelman, Alice T Shaw,[...]. J Thorac Oncol 2016
90
18

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Patrick C Ma, Takashi Kijima, Gautam Maulik, Edward A Fox, Martin Sattler, James D Griffin, Bruce E Johnson, Ravi Salgia. Cancer Res 2003
367
17

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P Lopez-Casas,[...]. Clin Cancer Res 2017
65
26

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
129
17

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, Davey B Daniel, Jerome H Goldschmidt, George R Blumenschein, Maciej J Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi,[...]. J Clin Oncol 2013
358
16


PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
115
16

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
15

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Sai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, Adrienne Johnson, Samuel J Klempner, Viola W Zhu, Vincent A Miller, Siraj M Ali. J Thorac Oncol 2017
70
21

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
L Schmidt, F M Duh, F Chen, T Kishida, G Glenn, P Choyke, S W Scherer, Z Zhuang, I Lubensky, M Dean,[...]. Nat Genet 1997
15

Molecular cloning of a new transforming gene from a chemically transformed human cell line.
C S Cooper, M Park, D G Blair, M A Tainsky, K Huebner, C M Croce, G F Vande Woude. Nature 1984
855
15

MET signalling: principles and functions in development, organ regeneration and cancer.
Livio Trusolino, Andrea Bertotti, Paolo M Comoglio. Nat Rev Mol Cell Biol 2010
808
15

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Mark M Awad, Giulia C Leonardi, Sasha Kravets, Suzanne E Dahlberg, Alexander Drilon, Sinead A Noonan, D Ross Camidge, Sai-Hong I Ou, Daniel B Costa, Shirish M Gadgeel,[...]. Lung Cancer 2019
42
35

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Katsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii. Cancer Sci 2008
155
14

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
14

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Ken Suzawa, Michael Offin, Daniel Lu, Christopher Kurzatkowski, Morana Vojnic, Roger S Smith, Joshua K Sabari, Huichun Tai, Marissa Mattar, Inna Khodos,[...]. Clin Cancer Res 2019
53
26

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
41
34

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Kurtis D Davies, Aprille Lomboy, Carolyn A Lawrence, Michael Yourshaw, Gregary T Bocsi, D Ross Camidge, Dara L Aisner. J Thorac Oncol 2019
43
32

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
46
30

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Russell W Jenkins, Geoffrey R Oxnard, Sheryl Elkin, E Kelly Sullivan, Jennifer L Carter, David A Barbie. Clin Lung Cancer 2015
69
18

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
88
14

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Jana Fassunke, Wolfgang Schulte, Yon-Dschun Ko, Andreas Schlesinger, Marc Bos,[...]. Clin Cancer Res 2015
107
13

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K Koblish, Leslie M Hall, Jordan S Fridman, Elham Behshad, Richard Wynn, Yu Li,[...]. Clin Cancer Res 2011
146
13

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, Takamasa Koga, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto,[...]. J Thorac Oncol 2019
45
28

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Magda Bahcall, Taebo Sim, Cloud P Paweletz, Jyoti D Patel, Ryan S Alden, Yanan Kuang, Adrian G Sacher, Nam Doo Kim, Christine A Lydon, Mark M Awad,[...]. Cancer Discov 2016
85
14

Expression and mutational analysis of MET in human solid cancers.
Patrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, Nithya Ramnath, Candace Johnson, Sascha Dietrich, Tanguy Seiwert, James G Christensen, Ramasamy Jagadeeswaran, Thomas Krausz,[...]. Genes Chromosomes Cancer 2008
227
12

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-Bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song,[...]. J Thorac Oncol 2017
50
24

Targeting MET Amplification as a New Oncogenic Driver.
Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa, Kazuto Nishio. Cancers (Basel) 2014
68
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.